耐信适应症

Indications: Gastroesophageal reflux disease (GORD) includes the initial and long-term treatment of erosive reflux esophagitis (including erosive esophagitis). It can be used for the long-term maintenance treatment of esophagitis and the prevention of GORD recurrence, as well as the symptomatic treatment of GORD disease. Used in combination with antibiotics to eradicate Helicobacter pylori, treat duodenal ulcers caused by Helicobacter pylori, and prevent the recurrence of Helicobacter pylori-related peptic ulcers. Nexium is a new generation of proton pump inhibitor (PPI), mainly suitable for the treatment of peptic ulcer. Compared with other proton pump inhibitors, Nexium has the advantages of shorter treatment course, more stable efficacy, faster and longer onset of action, and higher HP ulcer eradication rate. It is the latest generation of drugs currently used to treat peptic ulcers.

Nexium was approved for marketing in the United States and major European countries in 2001. It was launched in China in 2003 and entered the national medical insurance directory in November 2004, and the market was launched.

In a clinical comparative study of Nexium and omeprazole in the treatment of reflux esophagitis, the total effective rate of Nexium was 97.18%, which was significantly higher than 84.51% of omeprazole, and there was no significant difference in the incidence of adverse reactions. Chen Caiming has done a cost-effectiveness analysis of omeprazole and Nexium in the treatment of duodenal ulcer. The recovery rate of the Nexium group was 92.6%, which was higher than omeprazole's 78.6%. The results proved that Nexium has cost and effect advantages.

Nexium keeps the gastric pH > 4 longer. A study on the duration of gastric pH > 4 and the healing rate of reflux esophagitis showed that the longer the duration of pH > 4 within 24 hours, the greater the number of patients who healed after 8 weeks. After taking different drugs orally for 5 days, the duration of pH>4 in the stomach within 24 hours from longest to shortest is: Nexium 40mg, omeprazole 40mg, lansoprazole 30mg, pantoprazole 40mg and rabeprazole 20mg. This shows that Nexium 40mg has a stronger acid-suppressing effect than other proton pump inhibitors. Clinical trials have also fully confirmed the excellent pH control capabilities of Nexium 40mg. Generally speaking, it is very effective in treating early-stage gastric cancer.